Rebuttal From Drs Cazzola and Matera

[摘要] The motivations given by Barrecheguren and Miravitlles¹ against the need to use dual bronchodilation on diagnosis of COPD are scientifically sound and pragmatic. However, the therapeutic decisions for the treatment of patients with COPD are currently based on an evaluation of symptomatology and the risk of developing exacerbations, and there is evidence that long-acting muscarinic antagonist (LAMA) plus long-acting β₂-agonist (LABA) combinations, mainly fixed-dose combinations (FDCs), generally show improved outcomes such as St.

[学科分类] 呼吸医学